NeoGenomics CEO Chris Smith to retire April 1; board member Tony Zook named successor
NEOGENOMICS INC
Chris Smith retires as CEO effective April 1, 2025; will serve as special advisor through Feb 2027 at $23,913/month.
Tony Zook, independent board member since June 2023, appointed CEO effective April 1; base salary $850k with 100% target bonus and ~$8M annual equity target.
Smith's retirement package includes pro-rated 2025 bonus, accelerated vesting of 265,452 restricted shares, and 12-month option exercise extension.
Company reaffirms FY2024 guidance: revenue $655–$667M, net loss $(81)–$(78)M, adjusted EBITDA $37–$40M.
NeoGenomics reported eight consecutive quarters of double-digit revenue growth under Smith's tenure.
The Special Advisor Agreement provides that Mr. Smith will serve as a special advisor to the Company’s Chief Executive Officer until February 26, 2027 in exchange for a fee of $23,913 per month.
Christopher Smith, the Company’s Chief Executive Officer and a member of the Company’s board of directors (the “Board”), will retire effective April 1, 2025
Christopher Smith, the Company’s Chief Executive Officer and a member of the Company’s board of directors (the “Board”), will retire effective April 1, 2025
On January 10, 2025, the Company announced the appointment of Tony Zook to replace Mr. Smith as Chief Executive Officer effective April 1, 2025.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.85
Christopher Smith was appointed as special advisor at NEOGENOMICS INC.
Action
appointed
Role
special advisor
Exact text from the filing
The Special Advisor Agreement provides that Mr. Smith will serve as a special advisor to the Company’s Chief Executive Officer until February 26, 2027 in exchange for a fee of $23,913 per month.
Christopher Smith departed as Chief Executive Officer at NEOGENOMICS INC.
Action
retire
Role
Chief Executive Officer
Exact text from the filing
Christopher Smith, the Company’s Chief Executive Officer and a member of the Company’s board of directors (the “Board”), will retire effective April 1, 2025
Christopher Smith departed as member of the board of directors at NEOGENOMICS INC.
Action
retire
Role
member of the board of directors
Exact text from the filing
Christopher Smith, the Company’s Chief Executive Officer and a member of the Company’s board of directors (the “Board”), will retire effective April 1, 2025
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.